Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Pancreatic Ductal
  • Kidney Neoplasms
  • Liver Neoplasms
  • Lung Neoplasms
  • Pancreatic Neoplasms
  • Splenic Neoplasms

abstract

  • Our data confirmed that therapeutic efficacy of PTX and nab-PTX vary widely, and the contention that these agents elicit similar antitumour response was not supported. The addition of PTX to GEM showed no survival advantage, concluding that a clinical combination of PTX and GEM may unlikely to provide significant survival advantage over GEM monotherapy and may not be a viable alternative to the current standard-of-care nab-PTX plus GEM regimen for the treatment of PDAC patients.

publication date

  • August 9, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4985357

Digital Object Identifier (DOI)

  • 10.1038/bjc.2016.215

PubMed ID

  • 27441498

Additional Document Info

start page

  • 442

end page

  • 53

volume

  • 115

number

  • 4